Other languages Immunic, Inc.

Equities

IMUX

US4525EP1011

Real-time Estimate Cboe BZX Other stock markets 10:00:44 2024-06-05 am EDT			5-day change	1st Jan Change
1.21 ^USD	0.00%		-1.63%	-19.33%

May. 08	Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08	Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation	Apr. 30
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	Mar. 21
Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22
Immunic Launches 3-Tranche Private Placement of Up to $240 Million; Shares Rise	Jan. 05
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	Jan. 05
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket	Jan. 05
Top Premarket Gainers	Jan. 05
Immunic Files $250 Million Mixed-Securities Shelf Registration	Nov. 22
Immunic Receives Notice of Allowance From US Patent Office for Dosing Regimens for Treating Multiple Sclerosis	Nov. 21
Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts	Nov. 02
Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023	23-10-15
MÄRKTE USA/Aktien starten gut behauptet - Anleihen fest	23-10-10
MÄRKTE USA/Aktien gut behauptet erwartet - Anleihen fest	23-10-10
Top Premarket Gainers	23-10-10
Immunic Says Phase 2 Trial Reinforces Vidofludimus Calcium's Neuroprotective Potential; Shares Soar Premarket	23-10-10
Immunic Says Phase 2 Trial Further Reinforces Vidofludimus Calcium's Neuroprotective Potential; Shares Rise After Hours	23-10-09
Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis	23-10-09
Immunic Completes Enrollment for Calliper Trial Phase 2	23-08-17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Immunic, Inc.

Equities

IMUX

US4525EP1011

Other languages

Filters